ZURA BIO LIMITED Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent
ZURA BIO LIMITED (ZURA) had Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent of $2.36 million as of 2024-06-30, per its 10-Q filed 2024-08-13.
Financial Statements › Balance Sheet › Liabilities
us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent · last filed 2025-03-25
- 2024-06-30: Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent $2.36M.
- 2024-03-31: Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent $1.60M.
- 2023-12-31: Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent $990.00K.
- 2023-09-30: Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent $1.95M.
| Period end | Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent |
|---|---|
| 2024-06-30 | $2.36M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $1.60M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $990.00K 10-K · filed 2025-03-25 |
| 2023-09-30 | $1.95M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $2.07M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $1.54M 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |